Opinion
5don MSNOpinion
The price Americans pay for medicine has gotten horribly out of control. Here’s how to fix it.
We can start with laws that limit the power of pharmacy-benefit managers ...
Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, manufacturing, and ...
Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...
AbbVie stock is a "Buy" given its Q4 beat, Skyrizi/Rinvoq growth, and strong FCF. Here's what investors need to know about ...
Pfizer PFE and AbbVie ABBV are leading U.S. drugmakers with strong positions across multiple therapeutic areas. Oncology ...
PBM formulary exclusions top 600 drugs as Caremark, Express Scripts and Optum Rx adjust 2026 lists amid pricing shifts.
US drug prices are the highest globally, averaging 759% above the median, with Americans paying up to 800x more for common medicines ...
President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U. prescription drug prices in line ...
The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...
Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain. Pharmacy ...
Experts say this PBM request for proposal season could be among the most consequential employers have ever faced.
The latest international Puyaan Singh news and views from Reuters - one of the world's largest news agencies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results